Bremelanotide

This entry reviews the available information on bremelanotide, a cyclic peptide (molecular weight ~1025 Da), specifically in the context of breastfeeding safety. The review notes a complete absence of published clinical data on bremelanotide use during lactation. The authors reason that, based on its physicochemical properties as a large cyclic peptide, transfer into breast milk is theoretically expected to be minimal. Furthermore, even if trace amounts were present in milk, oral absorption by a nursing infant would likely be negligible, as the peptide would probably be degraded by proteolytic enzymes in the infant's gastrointestinal tract. Despite this theoretical reassurance, the review concludes that caution is warranted during breastfeeding due to the lack of empirical data, with particular emphasis on vulnerability in newborn and preterm infants, whose gastrointestinal and hepatic systems are less mature. The primary limitation of this entry is that it is entirely inference-based, drawing on pharmacokinetic principles rather than any direct human or animal lactation studies. No measured milk concentration data, infant outcome data, or controlled observations are cited.

Why this grade: This is a narrative review relying solely on theoretical pharmacokinetic reasoning with no clinical, animal, or in vitro lactation data for bremelanotide.